

September 2025 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Attruby (acoramidis)	Treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduced cardiovascular death and cardiovascular-related hospitalization.	Formulary	NA
Alhemo (concizumab)	Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, both with or without inhibitors to Factor VIII or IX respectively.	Formulary	NA
Hympavzi (marstacimab)	Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII or IX respectively.	Non-Formulary	NA
Qfitlia (fitusiran)	Routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 years and older with hemophilia A or B, both with or without inhibitors to Factor VIII or IX respectively.	Non-Formulary	NA

September 2025 Pharmacy & Therapeutics Committee Decisions

Crenessity (crinecerfont)	adjunct treatment to glucocorticoid (GC) replacement in adults and pediatrics 4 years and older with classic congenital adrenal hyperplasia (CAH)	Non-Formulary	NA
Revuforj (revumenib) Protected Class	treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in patients aged ≥ 1 year	Formulary w/PA	NA
Tryngolza (olezarsen)	An adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS)	Non-Formulary	NA
Vafseo (vadadustat)	Treatment of anemia due to chronic kidney disease (CKD) in adults receiving dialysis for ≥ 3 months	Non-Formulary	NA

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 10/1/2025.

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Dupixent (dupilumab) 200 & 300 mg SQ inj for chronic spontaneous urticaria	Formulary	No change
Nucala (mepolizumab) 100 mg SQ inj for COPD with an eosinophilic phenotype	Non- Formulary	No change
Jivi (recombinant antihemophilic factor, pegylated-aucl) for hemophilia A in pediatric patients = 7 years age expansion	Non- Formulary	No change

September 2025 Pharmacy & Therapeutics Committee Decisions

Zynyz (retifanlimab) 25 mg/mL IV vials for squamous cell carcinoma of the anal canal	Non- Formulary	No change
Susvimo (ranibizumab) 100 mg/mL vials for diabetic retinopathy	Formulary	No change
Welireg (belzutifan) 40 mg tablets for pheochromocytoma or paraganglioma	Formulary	No change
Nubeqa (darolutamide) 300 mg tablets approved as a single agent for metastatic castration sensitive prostate cancer	Formulary	No change
Gamifant (emapalumab) 5 mg/mL & 25 mg/mL IV vials for hemophagocytic lymphohistiocytosis/macrophage activation syndrome in known or suspected Still's disease	Non- Formulary	No change
Mavyret (glecaprevir/pibrentasvi) 100-40 mg tablets and 50-20 mg oral pellets for acute hepatitis C	Formulary	No change
Mresvia (Respiratory Syncytial Virus Vaccine) 50 mcg/0.5 mL injection for prevention of RSV in individuals 18-59 years of age at increased risk of disease	Formulary	No change
Tybest (cobicistat) 90 & 150 mg tablets for HIV in patients = 14kg indication expansion	Non- Formulary	No change

September 2025 Pharmacy & Therapeutics Committee Decisions

Datroway (datopotamab deruxtecan) 100 mg IV vial for EGFR-mutated non-small cell lung cancer	Non- Formulary	No change
Keytruda (pembrolizumab) 25 mg/mL IV vial for resectable locally advanced head & neck squamous cell cancer whose tumors express PD-L1I	Non- Formulary	No change
Monjuvi (tafasitamab) 200 mg IV vial in combo with lenalidomide & rituximab for relapsed or refractory follicular lymphoma	Formulary	No change
Dupixent (dupilumab) 300 mg SQ injection for bullous pemphigoid	Formulary	No change

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Aptiom (eslicarbazepine) 200, 400, 600, & 800 mg tablets for partial-onset seizures	Generic competition for Aptiom has launched, with at least 6 manufacturers marketing eslicarbazepine	Formulary
Qsymia (phentermine-topiramate) 3.75-23, 7.5-46, 11.25-69, & 15-92 mg ER capsules for chronic weight management	Two manufacturers have launched generic alternatives of phentermine/topiramate capsules. The generics are still considerably higher net cost than the brand was before generic entry.	Non-Formulary
Promacta (eltrombopag) 12.5 & 25 mg packets for	A single generic manufacturer has launched eltrombopag for all	Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

suspension & 12.5, 25, 50, & 75 mg tablets for chronic immune thrombocytopenia (ITP), thrombocytopenia in hepatitis C, & severe aplastic anemia	strengths of the tablets and packets for suspension. The first manufacturer has 180-day exclusivity, and significant reductions in price are not anticipated until after that expires. The new generic is approximately 10% reduction in AWP list price and 21% for WAC price.	
Jynarque (tolvaptan) 15 & 30 mg tablets & multi-strength therapy packs for autosomal dominant polycystic kidney disease	Generic tolvaptan, the equivalent of Jynarque, recently launched and is indicated for autosomal dominant polycystic kidney disease.	Non-Formulary
Complera (emtricitabine- rilpivirine-tenofovir df) 200-25-300 mg tablets for HIV-1 infection	A new generic for combination HIV treatment, emtricitabine/rilpivirine/tenofovir DF, has launched at approximately a 10% WAC discount to the branded agent.	Formulary
Tasigna (nilotinib) 50, 150, & 200 mg capsules for Philadelphia chromosome positive chronic myeloid leukemia	A new generic nilotinib has launched for all tablet strengths at a 5% (AWP) to 9% (WAC) discount to the branded agent.	Formulary
Merilog (insulin aspart-szjj) 100 unit/mL pens & vials (Novolog biosimilar)	A biosimilar insulin aspart product has launched in Merilog.	Non-Formulary
Fycompa (perampanel) 2, 4, 6, 8, 10, & 12 mg tablets for epilepsy	A generic perampanel (Fycompa equiv) product has launched at a 13% discount to the brand product.	Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

Xarelto (rivaroxaban) 1 mg/mL oral suspension for anticoagulation	Rivaroxaban 1 mg/mL oral suspension recently launched. Similar to the generic 2.5 mg oral tablets, brand Xarelto coverage will be maintained to continue to qualify for rebates on more common and still brand-only strengths	Non-Formulary
Eprontia (topiramate) 25 mg/mL oral solution for epilepsy & migraine	A generic topiramate 25 mg/mL oral solution has launched.	Non-Formulary
Imuldosa (ustekinumab-srlf) 45 mg/0.5mL PFS, 90 mg/mL PFS & 130 mg/26 mL IV vial and Pyzchiva (ustekinumab-ttwe) 45 mg/0.5 mL SQ vial for various inflammatory conditions	Another ustekinumab biosimilar launched, Imuldosa, by Accord biopharma. Imuldosa is available as a subcutaneous solution in a prefilled syringe and as a vial for intravenous use. A new biosimilar dosage form of Pyzchiva also launched, now as a vial for subcutaneous use.	Non-Formulary
Zepbound (tirzepatide) 12 mg/0.5 mL & 15 mg/0.5 mL SQ vials for weight management	Two new tirzepatide strengths recently launched, with both subcutaneous solutions only having AWP pricing and only available through the manufacturer for self-pay patients and are not contracted for clients who include weight loss coverage.	Non-Formulary
Carbzah (carbinoxamine) 4 mg/5 mL oral solution for seasonal allergies	Carbzah is a branded generic version of carbinoxamine solution. The price of this product is about 6X greater than the existing generics	Non-Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

Dificid (fidaxomicin) 200 mg tablets for Clostridioides difficile-associated diarrhea	Generic fidaxomicin recently launched. For Commercial/Exchange, Dificid is currently rebated with similar net cost to the generic. The brand rebate continues with the generic added at the same tier with the same utilization management.	Non-Formulary
Sertraline 150 & 200 mg capsules for major depressive disorder & obsessive-compulsive disorder	Both brand and generic products are \$5 or more per capsule, which is significantly more expensive than the tablet formulations which have been generic for a long time and have a MAC price < \$0.25 per tablet.	Non-Formulary
Fluticasone 50, 100, & 200 mcg/actuation AG inhalers for asthma (Arnuity Ellipta AG)	As a multisource brand product with only a 5% reduction in AWP price, it is significantly more expensive than the true brand product, which has a significant rebate available. For that reason, the AG remains not covered, while the branded product remains preferred on formulary	Non-Formulary
Entresto (sacubitril-valsartan) 24-26, 49-51, & 97-103 mg tablets for heart failure	After some legal battles, the temporary injunction preventing generic launch was lifted in late July. Several manufacturers have since launched their generic versions.	Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

New or Expanded Formulations		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
Miudella (copper IUD) for contraception	This product contains a lower copper content compared to Paragard, which is of unknown clinical significance. It also uses a more flexible material and improved applicator which may decrease pain during insertion and throughout the duration of use.	Non-Formulary
Livmarli (maralixibat) 10, 15, 20 & 30 mg tablets for Alagille syndrome & cholestatic pruritus in progressive familial intrahepatic cholestasis	Livmarli initially launched with only an oral solution available. New tablet formulations containing 10, 15, 20, or 30 mg of maralixibat have launched.	Non-Formulary
Edurant Ped (rilpivirine) 2.5 mg tablets for oral suspension for HIV-1 infection	Lower strength rilpivirine tablets for oral suspension launched supporting dosing in pediatrics at the same daily WAC cost as the standard 25 mg tablets used in older patients.	Formulary
Bucapsol (buspirone) 7.5, 10, & 15 mg capsules for anxiety	Buspirone oral capsules recently launched at a significantly higher cost than the same strength generically available tablets, which are covered on formulary and can be used instead of the capsules.	Non- Formulary
Khindivi (hydrocortisone) 1mg/mL oral solution for Adrenocortical insufficiency & Alkindi (hydrocortisone) sprinkle capsules formulary maintenance	Khindivi is a new oral solution formulation of hydrocortisone used as replacement therapy in pediatric patients = 5 years of age with adrenocortical insufficiency.	Non- Formulary
Nilotinib d-tartrate 50, 150, & 200 mg capsules for	Nilotinib d-tartrate capsules recently launched. They are a	Non- Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML)	different salt form than the generically available nilotinib (Tasigna), however, there is no difference in dosage or administration. Nilotinib d-tartrate capsules are higher cost than the existing generic formulation (\$183.59 vs \$176.25 per cap)	
Yeztugo (lenacapavir) 300 tablets & 463.5 mg/1.5 mL SQ vials for HIV Pre-Exposure Prophylaxis	Lenacapavir for HIV pre-exposure prophylaxis (PrEP) recently launched under the new brand name Yeztugo. Yeztugo is available in the same tablet and injection formulations as Sunlenca but is indicated for PrEP vs treatment.	Non- Formulary
Yutrepia (treprostinil) 26.5, 53, 79.5 & 106 mcg inhalation capsule for pulmonary arterial hypertension & pulmonary hypertension associated with interstitial lung disease	Yutrepia is a new 505(b)(2) approved inhaled treprostinil product. This is marketed to compete with Tyvaso and Tyvaso DPI for the treatment of pulmonary arterial hypertension	Non- Formulary
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) 1000 mg- 10,000 units/5 mL PFS for generalized myasthenia gravis & chronic inflammatory demyelinating polyneuropathy	A new prefilled syringe formulation has launched which is labeled to allow for self- or caregiver-administration, rather than being limited to healthcare provider administration.	Non- Formulary
Arbli (losartan) 10 mg/mL oral suspension for hypertension	A new commercialized losartan oral suspension product has launched under the brand name Arbli. It is indicated for use in children as young as six years old.	Non- Formulary
Fanapt (iloperidone) 1, 2, 6, &	Two new titration packs are	Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

8mg + 1, 2, & 6 mg titration packs for schizophrenia & bipolar I	launching, to accommodate additional dosing schedules for new starts.	
Lopressor (metoprolol) 10mg/mL oral solution for hypertension & angina	Metoprolol tartrate oral solution is now available in a 10 mg/mL strength	Non- Formulary
Averi (desogestrel-ethinyl estradiol-Fe) 0.15-0.3 mg tablet for contraception	Averi oral contraceptive tablets contain desogestrel, ethinyl estradiol, and iron. The cost is similar to other single-source brand oral contraceptives.	Non-Formulary
Ibuprofen 300 mg tablet for pain	A new tablet formulation of ibuprofen was approved through the generic approval pathway. This product provides a 300 mg strength, which has been discontinued for years. \$13 per tablet	Non-Formulary
Dicyclomine 40 mg tablets for irritable bowel syndrome	A new branded 40 mg strength for dicyclomine tablets has launched at a significantly higher price compared to the generically available 10 mg capsules and 20 mg tablets.	Non-Formulary
Spevigo (spesolimab) 300 mg/2 mL PFS for generalized pustular psoriasis	A higher strength prefilled syringe for Spevigo launched allowing for simpler administration, as the full monthly dose can now be administered as just one injection.	Non-Formulary

September 2025 Pharmacy & Therapeutics Committee Decisions

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 11/15/2025)	• Andembry • Lynozyfic • Onapgo • Yeztugo • Zevaskyn • Zusduri